CG ONCOLOGY INC (CGON) — insider trading
Health Care · NASDAQ
CG ONCOLOGY INC (CGON) has 47 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 12 open-market sales among the most recent 47 (latest 2026-10-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Kalofonos Isabel | Officer (Chief Commercial Officer) | Grant / award / vesting (derivative) | 92,000 | — | $0 | Form 4 |
| 2026-10-15 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-10-15 | POST LEONARD E | Director | Open-market sale | 500 | $62.48 | $31.2K | Form 4 |
| 2026-10-15 | POST LEONARD E | Director | Open-market sale | 500 | $61.65 | $30.8K | Form 4 |
| 2026-10-15 | POST LEONARD E | Director | Option exercise / conversion | 1,000 | $0.6 | $600 | Form 4 |
| 2026-09-15 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-09-15 | POST LEONARD E | Director | Open-market sale | 1,000 | $72.98 | $73.0K | Form 4 |
| 2026-09-15 | POST LEONARD E | Director | Option exercise / conversion | 1,000 | $0.6 | $600 | Form 4 |
| 2026-08-14 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-08-14 | POST LEONARD E | Director | Open-market sale | 1,000 | $74.54 | $74.5K | Form 4 |
| 2026-08-14 | POST LEONARD E | Director | Option exercise / conversion | 1,000 | $0.6 | $600 | Form 4 |
| 2026-07-15 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-07-15 | POST LEONARD E | Director | Open-market sale | 1,000 | $71.17 | $71.2K | Form 4 |
| 2026-07-15 | POST LEONARD E | Director | Option exercise / conversion | 1,000 | $0.6 | $600 | Form 4 |
| 2026-07-10 | Mulay James | Director | Option exercise / conversion (derivative) | 24,165 | — | $0 | Form 4 |
| 2026-07-10 | Mulay James | Director | Open-market sale | 24,165 | $75.16 | $1.82M | Form 4 |
| 2026-07-10 | Mulay James | Director | Option exercise / conversion | 24,165 | $26.63 | $643.5K | Form 4 |
| 2026-06-25 | Liu Brian Guan-Chyun | Director | Open-market purchase | 371,085 | $66.87 | $24.81M | Form 4 |
| 2026-06-24 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-24 | POST LEONARD E | Director | Open-market sale | 5,000 | $70.00 | $350.0K | Form 4 |
| 2026-06-24 | POST LEONARD E | Director | Option exercise / conversion | 5,000 | $0.6 | $3.0K | Form 4 |
| 2026-06-22 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-22 | POST LEONARD E | Director | Open-market sale | 5,000 | $65.00 | $325.0K | Form 4 |
| 2026-06-22 | POST LEONARD E | Director | Option exercise / conversion | 5,000 | $0.6 | $3.0K | Form 4 |
| 2026-06-15 | Mulay James | Director | Option exercise / conversion (derivative) | 1,310 | — | $0 | Form 4 |
| 2026-06-15 | Mulay James | Director | Option exercise / conversion (derivative) | 654 | — | $0 | Form 4 |
| 2026-06-15 | Mulay James | Director | Open-market sale | 1,310 | $60.12 | $78.8K | Form 4 |
| 2026-06-15 | Mulay James | Director | Option exercise / conversion | 1,310 | $12.59 | $16.5K | Form 4 |
| 2026-06-15 | Mulay James | Director | Open-market sale | 654 | $60.12 | $39.3K | Form 4 |
| 2026-06-15 | Mulay James | Director | Option exercise / conversion | 654 | $3.72 | $2.4K | Form 4 |
| 2026-06-04 | Graf Susan E | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-06-04 | Rossi Christina | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-06-04 | POST LEONARD E | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-06-04 | POST LEONARD E | Director | Option exercise / conversion (derivative) | 1,000 | — | $0 | Form 4 |
| 2026-06-04 | POST LEONARD E | Director | Open-market sale | 1,000 | $54.50 | $54.5K | Form 4 |
| 2026-06-04 | POST LEONARD E | Director | Option exercise / conversion | 1,000 | $0.6 | $600 | Form 4 |
| 2026-06-04 | Mulay James | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-06-04 | Tong Victor Edward Jr | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-06-04 | Liu Brian Guan-Chyun | Director | Grant / award / vesting (derivative) | 9,354 | — | $0 | Form 4 |
| 2026-04-17 | Mulay James | Director | Option exercise / conversion (derivative) | 15,600 | — | $0 | Form 4 |
| 2026-04-17 | Mulay James | Director | Open-market sale | 15,600 | $73.01 | $1.14M | Form 4 |
| 2026-04-17 | Mulay James | Director | Option exercise / conversion | 15,600 | $36.63 | $571.4K | Form 4 |
| 2026-04-15 | Kuan Arthur | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 271,600 | — | $0 | Form 4 |
| 2026-04-15 | DETORE JAMES M. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 90,574 | — | $0 | Form 4 |
| 2026-04-15 | Patterson Joshua F. | Officer (See Remarks) | Grant / award / vesting (derivative) | 45,266 | — | $0 | Form 4 |
| 2026-04-15 | Kasturi Vijay | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 79,216 | — | $0 | Form 4 |
| 2026-04-15 | Bellete Ambaw | Officer (President and COO) | Grant / award / vesting (derivative) | 107,508 | — | $0 | Form 4 |
Ask the chat about CGON's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CG ONCOLOGY INC (CGON).
Last updated 2026-10-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.